The World Health Organization (WHO) has officially recommended the use of lenacapavir, a long-acting injectable medication, as a new tool in the fight against HIV. This injection, administered just twice a year, is expected to boost global prevention efforts by offering a convenient alternative to daily oral pre-exposure prophylaxis (PrEP).
The move marks a significant step forward in HIV prevention, particularly for individuals at higher risk of infection who may struggle with daily pill routines. Lenacapavir’s extended protection could improve adherence and make preventive treatment more accessible in communities where HIV continues to spread rapidly.
According to WHO, lenacapavir should be integrated into existing HIV prevention programs alongside other proven methods, such as condoms, antiretroviral therapy, and oral PrEP. Health authorities believe that a broader range of options can help tailor prevention efforts to suit different populations and settings.
WHO’s endorsement follows rigorous scientific review and aligns with the organization’s ongoing commitment to ending AIDS as a public health threat by 2030.
